Oral anticoagulants reduce adverse events in intermediate-risk atrial fibrillation patients, SINGLE-AF trial shows
Source Summary
The SINGLE-AF clinical trial found that oral anticoagulant therapy reduced the risk of adverse clinical events in patients with atrial fibrillation at intermediate stroke risk compared with no anticoagulation. Results were presented at ESC Congress 2026 and published in the New England Journal of Medicine.
Why it matters
This trial provides clinical evidence that oral anticoagulants benefit a specific patient population previously considered at intermediate stroke risk, potentially expanding treatment recommendations for atrial fibrillation management.
